C-R1C8Retrotope
lipid peroxidation, stabilized PUFAs
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-R1C8
C-R1C8C-R1C8lipid peroxidation, stabilized PUFAs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
SSG Advises Retrotope, Inc. in the Sale of Substantially all of its Assets to RTMFP Enterprises Inc. – SSG Capital Advisors, LLC Join Our Mailing List Our People Careers Contact Us ABOUT US About Us History Our Approach Our People SERVICES Mergers & Acquisitions Private Placements Financial Restructurings Valuations TRANSACTIONS MEDIA ROOM Press Releases SSG in the News Press Kit Speaking Engagements Published Articles Video Vault Press Release Press Releases SSG in the News Press Kit Speaking Engagements Published Articles Video Vault SSG Advises Retrotope, Inc. in the Sale of Subs
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's dise
Contacts About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Contacts Contacts General Questions +1 (650) 437-0700 Media relations Tim Brons +1 (415) 675-7402 tbrons@vid
Retrotope | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Retrotope Website: Retrotope Business Area(s) Small Molecules Neurobiology Description Retrotope is developing a new class of drugs designed to combat the disease and cellular degeneration that results from lipid peroxidation (LPO). Their lead drug candidate, RT001, is currently in late-stage clinica
Norgen Biotek Corp - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Science About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Science Science LPO and Degenerative Disease All healthy human tissues undergo a physiological process of cellular
Home Retrotope Inc. (650) 437-0700 - Reinforcing the molecules of life to combat degenerative diseases About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Reinforcing the Molecule
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's dise
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors - Global Source Ventures Skip to content Toggle navigation Global Source Ventures Home Portfolio About News Contact News Return to News July 19, 2019 Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors Recent News selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis selectION Announces Positive Results from Phase 1b Clinical T
%PDF-1.7 %���� 13361 0 obj > endobj xref 13361 23 0000000016 00000 n 0000009476 00000 n 0000009673 00000 n 0000009724 00000 n 0000009792 00000 n 0000010178 00000 n 0000010219 00000 n 0000010258 00000 n 0000010886 00000 n 0000011035 00000 n 0000011179 00000 n 0000011548 00000 n 0000011620 00000 n 0000017968 00000 n 0000018165 00000 n 0000018484 00000 n 0000018976 00000 n 0000019048 00000 n 0000024722 00000 n 0000024913 00000 n 0000025215 00000 n 0000025719 00000 n 0000000756 00000 n trailer ]/Prev 14309498>> startxref 0 %%EOF 13383 0 obj >stream h��[{ ���f0�\ Ð�D�Ԅ��N��-�H.�$�R�t��=�T.Ֆ[B�]�d … 8>�k U��c-p�4/F� ��[��8��&��rd4 i0��i�@�#A�YV4O�]ֲ��:��8� & ���q��K{:rFp\�`i�߷�F���f &7�H� r �bʅ3 ���o�5 E��gs6�0 �t¹�0�� Y#&w=>ل%~�#�wd�ĭqG���6a��s�o� �~i�S�K����"U����x�����7&���X7�OFmҞ'���I�=��?���߾���g��}n�9>�R��W�hO��wy���Jޗ��$��(���#G|� U:RV�F#a�8sEfo)p���Mpi7�#� 9�E=U:R� X�����#�~ȟ��-��֞ף���Ԋ X������#���� �Ү�� r����!���,��.�q��#�)�td ���Րp�r7qdu�0��]#(�+_ �!|6� r�B���o��_틘�: ���?2��u��.�;�n�K?�˳�Խ���=aRN� @� ����Wݶ:f��-�.~� … ��)�y �� �v�Q#X#�dղ�j�]Z�47)� ]�4��\�ѐ ���jQW�bz�;��X�j2��F��iB[VU=rFp%.*�]��Q;��.g��CMW��Qw1����� �l�� u��E��V#y�j�+���*��b\Ǡ�����g��.��H������I $�$��@H����%� �.�D�@�h�pVm�-� ���q�G��,�ɗ� j���͌�m�� @.�N�%(��� �� �G� {��٘cm�/�I�7E�*x���K�#�l����NZf�v�%� ��[}b2 �ZW�xV�2�Hpiݶ�B��9��sR��#~�Wd��PuI����'�QX��9��?�NpD��v��� g2��F5�F�M>����9 )�&mI��= t�d��:w�����H���㎰O�$��@HI $$p��ӊ�x�� � J �Ѥ�2�^�AF�J ��� �O�#�m����SS� … 53 0 obj > endobj 13354 0 obj > endobj 13355 0 obj > endobj 13356 0 obj >stream application/pdf Michaela Honelova Microsoft Word 2024-06-20T14:14:59Z 2024-06-24T09:37:39+02:00 2024-06-24T09:37:39+02:00 uuid:6675D707-0349-4F88-B958-AB56250FF99D uuid:1ce78016-eff0-cf4c-82a4-8539105dd432 default 1 converted uuid:24c8d301-5c3c-4b40-873c-5bf182cb4465 converted to PDF/A-2u Preflight 2024-06-24T09:37:36+02:00 PDF24 2 U http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema internal A nam
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration November 2, 2017 | 3 min read Twitter LinkedIn Facebook Email Print Stryker Nabs FDA OK for Cementless Mako Total Knee Physicians collaborating with Retrotope pre … ting Chief Medical Officer of Retrotope, added, “We applaud FDA’s conclusion to grant orphan designation using an inherited enzyme defect to define the molecular basis of disease. We are energized and excited by the potential of RT001 in this whole class of indications encompassed by FDA’s designation of PLA2G6-Associated Neurodegeneration, including INAD, non-infantile onset PLAN, and even PLA2G6 induced young-onset Parkinson’s disease (YOPD). About INAD INAD is an ultra-rar … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit October 19, 2021 | 7 min read Twitter LinkedIn Facebook Email Print Retrotope, today announced that positive results from precl … irment worldwide. The company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter. The first presentation, entitled, “Examine Iron-induced Oxidative Stress & Inflammation in a New Mouse Model of GA,” is being delivered by Josh Dunaief, M.D., Ph.D., Adele Niessen Professor of Ophthalmology, FM Kirby Center for Molecular Ophthalmology Scheie Eye Institute, U … indings in any dose group, further supporting the company’s plan to file an IND application for the program. RT011 is an isotopically stabilized, synthetic docosahexaenoic acid (DHA) discovered and developed with Retrotope’s novel platform technology. This platform is designed to combat the oxidative stress and cellular degeneration that arises from LPO. While all healthy human tissues undergo this physiological process of cell degeneration and repair, it is now well-establis … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-
Retrotope Announces Opening Of Second Clinical Trial Site For Enrollment In Friedreich's Ataxia Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Retrotope Announces Opening Of Second Clinical Trial Site For Enrollment In Friedreich’s Ataxia Clinical Trial November 20, 2015 | 3 min read Twitter LinkedIn Facebook Email Print LOS ALTOS, Calif. , Nov. 20, 2015 /PRNewswire/ -- Retrotope announces the opening of second clinical trial site, the Collaborat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)Three clinical trials centers now open for enrollment; two additional ones initiating - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUB … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)Three clinical trials centers now open for enrollment; two additional ones initiating January 9, 2020 | 4 min read Twitter LinkedIn Facebook Email Print Retrotope announced that … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developmen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications February 25, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Retrotope, a clinical-stage biopharmaceutical company focused on the development of n … her that can be redeemed to receive a priority review of a subsequent marketing application for a different product or sold to other companies. Retrotope is eligible to receive a priority review voucher should the company secure approval for RT001 in either one of these indications. The FDA’s Fast Track program is designed to facilitate the development, and expedite the review of, medicines to treat serious or life-threatening conditions and fill an unmet medical need. Recipi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Retrotope And Collaborators To Present Poster At American Academy of Neurology On Stabilized PUFA Drug Efficacy In Multiple Alzheimer’s Models - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufa … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Retrotope And Collaborators To Present Poster At American Academy of Neurology On Stabilized PUFA Drug Efficacy In Multiple Alzheimer’s Models April 25, 2017 | 3 min read Twitter LinkedIn Facebook Email Print D-PUFA stabilized fatty acid drug combination reverses Alzheimer’s cognitive losses … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Retrotope Drug Improves Survival in Ultra-Rare Genetic Childhood Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Retrotope Drug Improves Survival in Ultra-Rare Genetic Childhood Disease October 6, 2021 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print Retrotope cited data from its Phase II/III trial of RT001 in patients with infantile neuroaxonal dystrophy and reported … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
https://www.biospace.com/world-s-top-100-doctors 2020-01-02 https://www.biospace.com/phoenix-rehabilitation-and-health-services-acquires-physical-therapy-etc 2020-01-02 https://www.biospace.com/fountain-medical-appoints-mr-ling-zhen-as-the-co-chairman-and-chief-executive-officer 2020-01-02 https://www.biospace.com/the-european-medicines-agency-accepts-the-regulatory-submission-for-lumoxiti-in-relapsed-or-refractory-hairy-cell-leukemia 2020-01-02 https://www.biospace.com/tlc-to-present-at-38th-annual-jp-morgan-healthcare-conference 2020-01-02 https://www.biospace.com/aridis-pharmaceuticals-appo … /www.biospace.com/mesoblast-submits-clinical-efficacy-and-safety-data-to-fda-in-rolling-biologics-license-application-for-remestemcel-l 2020-01-02 https://www.biospace.com/vascepa-approved-in-canada-to-reduce-the-risk-of-cardiovascular-events 2020-01-02 https://www.biospace.com/exact-sciences-to-participate-in-j-p-morgan-healthcare-conference 2020-01-02 https://www.biospace.com/hexo-corp-closes-us-25-0-million-registered-direct-offering 2020-01-02 https://www.biospace.com/hex … anoprost-ophthalmic-solution-0-02-percent-0-005-percent-marketing-authorisation-application-in-europe 2020-01-02 https://www.biospace.com/teleflex-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference 2020-01-02 https://www.biospace.com/johnson-and-amp-johnson-announces-quarterly-dividend-for-first-quarter-2020 2020-01-02 https://www.biospace.com/merck-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference 2020-01-02 https://www.biospace.com/axogen-inc-to-par … /overcoming-barriers-to-pharma-market-access-in-emerging-markets-request-a-free-proposal-from-infiniti-s-pharma-industry-experts-for-detailed-insights 2020-01-02 https://www.biospace.com/pacific-college-of-oriental-medicine-to-change-name-to-pacific-college-of-health-and-science 2020-01-03 https://www.biospace.com/saspine-to-expand-locations-to-accommodate-rapid-growth-and-demand 2020-01-02 https://www.biospace.com/global-call-to-action-on-familial-hypercholesterolemia-aims-t … sus-host-disease 2020-01-02 https://www.biospace.com/dicerna-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-jan-2-2020 2020-01-03 https://www.biospace.com/2020-syngenta-crop-challenge-in-analytics-prize-committee-announced 2020-01-03 https://www.biospace.com/hackensack-university-medical-center-is-first-in-the-nation-to-acquire-the-t
Anil Kumar, MBA About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Management Anil Kumar, MBA Anil Kumar, MBA President and Director Anil Kumar Anil Kumar is an experienced
Exhibitor Profile - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Patients at center of 8th annual FARA-USF scientific symposium - USF Health NewsUSF Health News Education Research Patient Care News USF Contribute University of South Florida University of South Florida Medicine Nursing Public Health Pharmacy Patient Care Research News Search Quick Links Education Research Patient Care News USF Contribute End container-fluid div --> Patients at center of 8th annual FARA-USF scientific symposium Written by Anne DeLotto Baier · October 16, 2016 @ 1:51 pm · Filed under Hot News , Morsani College of Medicine , Neurosciences & Brain Repair , Research
Natural History of Infantile Neuroaxonal Dystrophy ClinicalTrials.Veeva Search CTV Search for a location Search for trials trials Find clinical trials Close Menu Share Share trial Follow Follow trial Natural History of Infantile Neuroaxonal Dystrophy R Retrotope Status Completed Conditions INAD Infantile Neuroaxonal Dystrophy Study type Observational Funder types Industry Identifier s NCT03999814 RT-INAD-NH001 Take notes View location Details and patient eligibility About This is a retrospective and cross-sectional review of the natural history of INAD. Full description After obtaining informe
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Retrotope, Inc. – SSG Capital Advisors, LLC Join Our Mailing List Our People Careers Contact Us ABOUT US About Us History Our Approach Our People SERVICES Mergers & Acquisitions Private Placements Financial Restructurings Valuations TRANSACTIONS MEDIA ROOM Press Releases SSG in the News Press Kit Speaking Engagements Published Articles Video Vault CLIENT TRANSACTIONS Retrotope, Inc. Client Profile Retrotope, founded in 2006 and based in Los Altos, California, is a clinical stage biotechnology company developing drugs to combat serious and debilitating neurological and retinal degene
Retrotope - Global Source Ventures Skip to content Toggle navigation Global Source Ventures Home Portfolio About News Contact Retrotope Retrotope’s drug platform, deuterium stabilized PUFAs, aims to preserve and restore mitochondrial health in degenerative diseases including Parkinson’s, Alzheimer’s, and diabetic retinopathy, among others. The unique mechanism of this new category of drugs prevents cellular damage and recovers cellular function damaged by lipid peroxidation. Post navigation RetroSense Theraputics Telephus Medical Home Portfolio About News Contact © 2026 Global Source Vent
Retrotope looks to fund neurodegenerative disease platform Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Service … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia … tterstock Retrotope is aiming for a $100m round in the first quarter of 2022 to fund late-stage development of an extensive neurodegenerative disease platform. California-based Retrotope’s lead asset, RT001, is a synthetic linoleic acid that fights cellular degeneration and oxidative stress caused by lipid peroxidation, chief medical officer Peter Milner explained. Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged pro
Videos About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Videos Videos February 16, 2021 Anil Kumar, Retrotope’s president and chief business officer, gave a corporate pres
Dr Mikhail Shchepinov, Retrotope's CSO, is to present at 9th International Singapore Lipid Symposium
Video about Retrotope’s Friedreich’s ataxia study About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home News Videos Video about Retrotope’s Friedreich’s ataxia study Video abou
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
%PDF-1.6 %���� 6473 0 obj > stream x��gP��OwO � C�!A��$�$A��� F�&dqVI� �� �.AVQŀ((`@w�E@YW� ��ު{�?o��~�~��S���>U�T d�9I��I�4���=38$�� $ � ��d; O �������(�V��t���[Dn� �r +������ F���f�7`�)�;S; e7 =g���,@�)'���-C� h@@2@�M� ����� �o�B�F�� �A&��@>(%� ���4�Vpt���2�n��` �=�j �MFˣu�h7t0:���G�������� �a`X3�+&���ac�0�0C�I�����`����l6 [�=��� �Na��8%�����rq�f\n7�[���xo &� A�0��H�(�h��!1C�R5�NT.5�z�z�:ICh�4����@�J��c�,�=�^H��>H���JKJn���� )` �#�Q�8�e|�R������+�*5,�(-'m+ %] �&="�Q�)�$� �_�S�,JV[�W6S���U�99��� G�@��#yX^[�O>[�����
Publications About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Science Publications Publications 2019 – Present 2016 - 2018 2013 - 2015 December 2021 Characterization of a
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account October 19, 2021 07:00 ET | Source: Retrotope Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rat
FARA - 🔉 Save the Date! Retrotope is hosting an... Facebook Log In FARA's Post FARA October 8, 2019 · Shared with Public Save the Date! Retrotope is hosting an Informational Patient Webinar on October 21st at 7pm to learn about RT001, a candidate molecule for the treatment of Friedreich’s Ataxia . #CureFA ••• To join by video system, click here once the meeting starts bit.ly/35l2RdY . Then, click join meeting and enter your meeting number. You can also join by phone +1-510-338-9438 USA Toll Access code: 628 791 460 All reactions: 38 8 comments 13 shares Like Comment Most relevant Wendi P
Friedreich’s Ataxia (FA) About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Patient Resources Friedreich’s Ataxia (FA) Friedreich’s Ataxia (FA) Friedreich’s ataxia (FA) is a
Retrotope Presents Data Demonstrating Arrest of Disease --> Accessibility: Skip TopNav Retrotope Presents Data Demonstrating Arrest of Disease Progression with Treatment of RT001 in Patients with Infantile Neuroaxonal Dystrophy (INAD) October 15, 2018 07:30 ET | Source: Retrotope Retrotope Results presented at the 2018 National Organization for Rare Disorders (NORD) Rare Diseases & Orphan Products Breakthrough Summit® LOS ALTOS, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Retrotope today reported new data that demonstrate arrest of disease progression with treatment of RT001 in patien
Retrotope - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Development 2 Clinical trials Toggle Clinical trials subsection 2.1 Friedreich's ataxia 2.2 Phospholipase 2G6-associated neurodegeneration 2.3 Infantile neuroaxonal dystrophy 3 Other clinical use Toggle Other c … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Retrotope 1 language Ad
Retrotope Doses First Patient with RT001 for Friedreich’s Ataxia Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About FA Toggle menu: About FA What is FA? Causes Symptoms Diagnosis Life expectancy Treatments Approved treatment: Skyclarys Experimental Treatments Non-drug Treatments Living with Toggle menu: Living with Living with FA Exercise and physiotherapy Diet Occupational therapy Speech therapy Adaptive equipment Late-onset FA Mental health Support and resources Community Toggle menu: Community Perspectives Defining Yourself — Jean Walsh My Darlin
Parkinson’s Institute and Clinical Center and Retrotope --> Accessibility: Skip TopNav Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients October 04, 2018 08:00 ET | Source: Retrotope Retrotope SUNNYVALE and LOS ALTOS, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Parkinson’s Institute and Clinical Center, which provides comprehensive patient care, while discovering new treatment options to improve the quality of life for all Parkinson’s disease (PD) patients, and Retrotope announced today a collabo
FARA - 🔉 Save the Date! Retrotope is hosting an... Facebook Log In FARA's Post FARA October 15, 2019 · Shared with Public Save the Date! Retrotope is hosting an Informational Patient Webinar on October 21st at 7pm to learn about RT001, a candidate molecule for the treatment of Friedreich’s Ataxia . #CureFA ••• To join by video system, click here once the meeting starts bit.ly/35l2RdY . Then, click join meeting and enter your meeting number. You can also join by phone +1-510-338-9438 USA Toll Access code: 628 791 460 All reactions: 25 1 comment 1 share Like Comment Most relevant Padraig C
Peter G. Milner - Renexxion - Ireland Home Company Our Vision Our Leadership Team Naronapride (ATI-7505) About Naronapride (ATI-7505) Mechanism of Action Development Status Chemistry and Manufacturing Regulatory Developments Knowledge Centre Gastrointestinal Dysmotility in Cystic Fibrosis (CF) Gastroparesis Chronic Idiopathic Constipation Irritable Bowel Syndrome PPI non-responsive GERD News Press > Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis ​ … and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories Renexxion to Present at the Oppenheimer 34ᵗʰ … enexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride ​Renexxion to Present at the Oppenheim … ith gastroparesis Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders Renexxion Ireland Ltd. Announces a Lic … rofitable transporter biology company that was sold in 2018 to a private equity fund Arsenal Capital. In 1997 Peter co-founded ARYx Therapeutics (ARYX) where as CEO, then as president from 2005 to 2010, he co-invented and developed 4 novel drugs and conducted 12 different Phase 1, 2 and 3 global clinical trials. In 1990 Peter co-founded CV Therap
Careers About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Careers Careers We pioneer with real-world impact. By inspiring collaboration between employees and industry partn
Retrotope announces open enrollment for Friedreich's ataxia clinical trial Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multim … rships with academic collaborators who have tested RT001 in FA cellular models, grant support for manufacturing, attendance at regulatory meetings and engagement of the patient community in focus group discussions on diet modifications recommended for this early phase study. We are excited to continue our partnership and support as we approach this new and important mileston e," said Jennifer Farmer , MS, CGC, Executive Director at FARA. Two of FARA's Collaborative Clinical R … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Careers About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Careers Careers We pioneer with real-world impact. By inspiring collaboration between employees and industry partn
PCC | Insilico Medicine Main About Mission Leadership Board of Directors Scientific Advisory Board Security & IT Contact us Pharma.ai Pharma.ai Suite PandaOmics Generative Biologics Chemistry42 inClinico Science42: DORA Nach01 MMAI Gym Pipeline News & Media Press Releases Blog Media Coverage Publications Events Media Kit Design Kit Investor Relations Investor Relations Corporate Governance Listing Documents Announcements & Circulars Webcasts & Presentations ESG Contact IR & Email Alert Careers MMAI Gym Benchmarks Insilico Science AI Bench Insilico Bench Drug Discovery Bench … ata generated at each step of the drug discovery process, making it a lucrative application for modern AI technologies. The application of such technologies has been shown to be beneficial at pretty much every step of the drug discovery process — especially at the hypothesis generation and target identification stage. Deep learning models and natural language processing technologies are compelling when modeling large complex multi-dimensional data sets, such as genomics, prot
Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manuf … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients October 4, 2018 | 5 min read Twitter LinkedIn Facebook Email Print Parkinson’s Institute and Clinical Center and Retrotope announced today a collabor … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies — Foundation Fighting Blindness Stay up to date on the latest Foundation news and research. Join Today! Close Skip to main content Skip to footer Foundation Fighting Blindness homepage Search My Chapter: Arizona Atlanta Austin Baltimore Charlotte Chicago Cincinnati/Northern Kentucky Cleveland Colorado Columbus Dallas-Fort Worth D.C. Metro Eastern Michigan Fort Wayne Greater New York Hampton Roads/Virginia Beach Houston Indianapolis Jacksonville Kansas City Las Vegas Los Angeles Maine Miami Naples … Region Washington Wisconsin View Chapter Donate Give Monthly Menu Close Search Submit Understanding Vision Loss Understanding Vision Loss Vision Loss Glossary Retinal Education Videos Achromatopsia Bardet-Biedl Syndrome (BBS) Best Disease Choroideremia CRB1-Associated Diseases Geographic Atrophy (GA) Leber Congenital Amaurosis (LCA) Macular Degeneration PRPH2-Associated Diseases Retinitis Pigmentosa Refsum Disease Stargardt Disease Thyroid Eye Disease Usher Syndrome X-Linked … um VISIONS (United in Vision) Conference Awareness Calendar United In Vision RD Fund Genetic Testing For ECPs About Mission & History Board of Directors Leadership Strategic Council Scientific Advisory Board National Trustees Corporate Partners Financials & Governance Annual Reports Careers Contact Ways to Give Credit Card, ACH & PayPal Tribute Donations Legacy Giving Donor Advised Funds Stock Donations Crypto Donations IRA Charitable Rollover Join a VisionWalk Ho … been part of Vedere Bio’s pipeline. (Vedere is a company in the Foundation’s RD Fund portfolio.) Its original optogenetic therapy expresses a medium-wave green cone opsin that is thought to be more responsive to natural light than other optogenetic alternatives. In late 2020, Novartis acquired Vedere and that original cone opsin-based therapy. Subsequently, Vedere II, a new company, was launched to advance an optogenetic therapy that combines an opsin-like protein with a chem … on in people with RP, Usher syndrome, and other conditions. A company in the RD Fund portfolio, SparingVision, plans to launch a clinical trial for RdCVF in 2022. The company is also developing a treatment to restore function to cone photoreceptors that remain alive but have lost their ability to process light. Halden Conner, chief executive offi
Parkinson’s Institute and Clinical Center, Retrotope to Test RT001 in PSP Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About Parkinson's Toggle menu: About Parkinson's What is Parkinson’s disease? Causes Diagnosis Symptoms Motor symptoms Nonmotor symptoms Types Treatments Approved treatments Experimental treatments Non-drug treatments Living with Toggle menu: Living with Exercise Diet Parkinson’s progression News Community Toggle menu: Community Awareness Month Perspectives The Bright Side – Jamie Askari The Impatient Patient – Doc Irish Living My B
Retrotope - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners T … ent topics include: fatty acids rare diseases alkenoic acids View Patents Chart Application Date Grant Date Title Related Topics Status 3/1/2022 10/8/2024 Synergistic combination therapy for treating als Prodrugs, Fatty acids, Rare diseases, Neurological disorders, Syndromes Grant Application Date 3/1/2022 Grant Date 10/8/2024 Title Synergistic combination therapy for treating als Related Topics Prodrugs, Fatty acids, Rare diseases, Neurological disorders, Syndromes Status Gr
MedStars - Bob Molinari, Healthcare Business Consulting Home About Services Portfolio Blog Contact Resources More Home About Services Portfolio Blog Contact Resources Home About Services Portfolio Blog Contact Resources Bob Molinari - MedStars Bob Molinari In 2023, Bob Molinari became the founding CEO of a new neuro/retinal disease company (currently in stealth mode) focused on a novel small molecule drug that inhibits enzymes that disrupt fatty acid metabolic homeostasis in the brain and retina, simultaneously downregulating neuroinflammation, lipid damage, protein aggregat
Retrotope Inc投融资最新情况_摩熵医药 点我 免费 申请试用企业版 --> 洞察市场格局 解锁药品研发情报 客服电话 400-9696-311 邀请有礼 掌上免费使用 生物医药个人版数据库 掌上数据库 --> 医药数据查询 您尚未登陆，请先登录吧 登录 亿鸽在线客服系统 --> 生物医药全产业链数据服务平台 企业版官网 掌上数据 打开微信扫一扫 我要投稿 网站导航 数据开放平台 产品矩阵 --> 摩熵数科产品矩阵 查看详情 {{ item.category }} {{ product.info.name }} {{ product.info.desc }} {{ listItem.name }} 快速筛选药品，用摩熵药筛 微信扫一扫-立即使用 登录 / 免费注册 首页 个人版 企业版 院销智策 摩熵咨询 咨询服务 产品立项评估及管线规划 数据定制服务 产业/行业调研 市场洞察咨询服务 投资决策与交易估值 “十五五”战略规划 资源大厅 报告大厅 已收录 115687 份 摩熵说直播 最新 全球"超级重磅炸弹"药物阿托伐他汀（第一期） 资讯 摩熵原创 深度分析 过评精选 政策法规 赛道梳理 投融资 注册审批 时讯 科普 医药洞见 会议 摩熵视野 前沿研究 招标采购 公司动态 财报业绩 临床研究 医保动态 研
Retrotope Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Retrotope Retrotope Los Altos, CA Watchlist Export About Financials People Deals Funding About Retrotope Company overview Retrotope is a privately-held company that operates in the pharmaceuticals industry. Retrotope was founded in 2006 by Mikhail Shchepinov and Robert Molinari. Retrotope headquarters are located in Los Altos, California. Keywords Revenue Revenue EBITDA EBITDA Valuation Valuation Income Statement Line Item 2024 2023 2022 2021 2020 Revenues $380 MM $250 MM $90 MM $120 MM $65
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Retrotope Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners Turb
%PDF-1.5 %���� 356 0 obj > endobj xref 356 35 0000000016 00000 n 0000002061 00000 n 0000002175 00000 n 0000003295 00000 n 0000003322 00000 n 0000003453 00000 n 0000003569 00000 n 0000003606 00000 n 0000003720 00000 n 0000005012 00000 n 0000006213 00000 n 0000007453 00000 n 0000008657 00000 n 0000009818 00000 n 0000011037 00000 n 0000011765 00000 n 0000011853 00000 n 0000012401 00000 n 0000013041 00000 n 0000014184 00000 n 0000015537 00000 n 0000018186 00000 n 0000023111 00000 n 0000058576 00000 n 0000058615 00000 n 0000058690 00000 n 0000059245 00000 n 0000124917 00000 n 0000125269 00000 n 000 … ���m���^�소�>�|��)�g rvw6 �} �� ��o�X���F� endstream endobj 378 0 obj >stream application/pdf FARA LOGO1C_WH 2014-11-08T12:07:42-05:00 2014-11-08T12:07:42-05:00 2014-11-08T12:07:42-05:00 Adobe Illustrator CC (Macintosh) uuid:654c7960-10ee-164c-b265-6bdbc7b4bfbd xmp.did:e76e979d-7327-43c8-b792-7f82eb0cbe15 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:3f95aa7c-10e3-344a-8365-344323fe6d4a xmp.did:A20F2033DE2068118083AB6F9E802119 uuid:5D20892493BFDB11914A8590D31508C8 pr … 0644WH�����5Pp�� �0@}Z endstream endobj 384 0 obj > endobj 385 0 obj >stream application/postscript Печать Crystal Wade 2021-05-10T08:37:57-07:00 2021-05-10T08:37:57-07:00 2021-05-10T08:37:57-07:00 Adobe Illustrator 25.0 (Macintosh) xmp.iid:321f46b3-8924-4f12-857b-f82fba148afc xmp.did:321f46b3-8924-4f12-857b-f82fba148afc uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:42d85ff5-1bf7-43ce-bd20-7e4c3bafd283 xmp.did:42d85ff5-1bf7-43ce-bd20-7e4c3bafd283 uuid:5D20892493B … 25D6 2017-01-24T08:32:04+02:00 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6268D74EE3E2E611822EEF47542D08A3 2017-01-25T11:47:38+02:00 Adobe Illustrator CS6 (Windows) / saved xmp.iid:C072118EEFE2E611822EEF47542D08A3 2017-01-25T13:15:18+02:00 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:E89148AE7D01E71199F984A2238005F1 2017 … 05F1 2017-03-05T10:33:53+02:00 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6CE12C828301E71199F984A2238005F1 2017-03-05T11:09:59+02:00 Adobe Illustrator CS6 (Windows) / saved xmp.iid:6EE12C828301E71199F984A2238005F1 2017-03-05T11:14:16+02:00 Adobe Illustrator CS6 (Windo
Peter D. Milner, MD About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Management Peter D. Milner, MD Peter D. Milner, MD Chief Medical Officer Peter D. Milner Peter D. Miln
EyeWorld Weekly, October 22, 2021 - EyeWorld Skip to content Search... Submit search Sections ASCRS News Cataract Refractive Cornea Glaucoma Practice Management Issues Current issue Issue archives Online Exclusives EyeWorld Weekly Latest EyeWorld Weekly EyeWorld Weekly archives Sign up Non-CME Programs & Projects Corporate Replay Corporate Educational Events Supplements Menu Close Sections ASCRS News Cataract Refractive Cornea Glaucoma Practice Management Issues Current issue Issue archives Online Exclusives EyeWorld Weekly Latest EyeWorld Weekly EyeWorld Weekly archives Sign up Non-CME P … by the European Medicines Agency with intent to file a Marketing Authorization Application in the first half of 2022. If approved, polihexanide would become the first drug approved in Europe for treatment of Acanthamoeba keratitis. Back to top Research on first-in-class therapy for retinal degenerative disease Retrotope, a clinical-stage company, announced positive results from its preclinical studies of RT011, which it described as a novel technology platform be … cal program for dry AMD with an expectation to file an Investigational New Drug application in the first half of 2022 followed by the first-in-human clinical studies. Back to top ASCRS news and events 20/Happy in 2021: The popular ASCRS Master Class in Refractive Cataract Surgery is back with a new CME module— 20/Happy in 2021 —hosted in person during the AAO Annual Meeting in New Orleans, Louisiana. If you’re attending the AAO Annual Meeting, join in the complimentary
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP) February 18, 2020 | 5 min read Twitter LinkedIn Facebook Email Print Retrotope announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted … tributed to the results supporting our filing an investigational new drug (IND) application to FDA in this terrible disease.” Peter Milner, MD, Chief Medical Officer of Retrotope, added, “PSP is a disease involving modification and dysfunction of tau protein. RT001’s mechanism of action both lowers lipid peroxidation and prevents mitochondrial cell death of neurons which is associated with disease onset and progression. Also RT001 has a synergistic downstream benefit in the p … s of the ODA, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated. About RT001 RT001 is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochon … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Green Park & Golf Ventures — VC Fund Profile | Waveup Copilot Assisted fundraising Log in | Sign up Home Guides Assets Investors VC funds Tailored lists Favorites Academy Privacy policy Terms of Use Privacy Policy Help center Return to waveup.com Fund profile Green Park & Golf Ventures Dallas, USA Not leading About Green Park & Golf Ventures (GPG Ventures) is a Dallas-based healthcare-focused venture capital firm founded in 2011, built on more than 60 years of combined operational and financial experience in the healthcare sector. The firm is led by co-founders Dr. Clay Heighten and Ca … lter by Sort by Contacts Website gpgventures.com Social Lists that include this fund
Jan 27-29, 90+ Exhibitors at PMWC 2027 Silicon Valley Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to spea … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Global Source Ventures - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubator … till date : $44.1M Employee Count : 22 as on Apr 30, 2026 Investors : Founders Fund , Global Source Ventures and 23 Other s Latest Funding Round : Series B, May 28, 2024 , $ ***** Highlight : Editors' Pick 5 . SelectION selectION provides screening and development platform for drugs. The company provides ion channel blockers by targeting additional potassium, sodium, calcium, and chloride channels, which will lead to other clinical applications in pain management and on
%PDF-1.6 %���� 533 0 obj > endobj 549 0 obj >/Filter/FlateDecode/ID[ ]/Index[533 29]/Info 532 0 R/Length 91/Prev 386952/Root 534 0 R/Size 562/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"g�I��"���� �}1�l.���^�ءS��@�I ��DJ��5���U L� L`q�������VW/ endstream endobj startxref 0 %%EOF 561 0 obj >stream h�b```�. af`��0p aah�b �`����&�n{��a�� F姉�aB�0��������D�� }@ ���=H�1?X�*�����7�S�;�����g�v֞�l#)� �\��( � f@���A��Ty�g�@��� =�"� endstream endobj 534 0 obj >/Metadata 29 0 R/PageLayout/OneColumn/Pages 531 0 R/StructTreeRoot 41 0 R/Type/Catalog>> endobj 535 0 … 11fea8b-3e79-4c9d-9043-65f5ff96852b uuid:27ab6969-139c-4a99-b261-6d018b4c1d09 5 application/pdf Saame Raza Shaikh Adobe PDF Library 19.12.68 D:20190923192836 ECU endstream endobj 30 0 obj >stream h�256T0P���w�/�+Q0���L)�656�)�Is0i �J@Č @T�~HeA�~@bzj�� @��k endstream endobj 31 0 obj >stream h�l�� �@@�W�;uQΏ�F��*�$Z_��]��7AD���J+��Ļi�� q�p�'Bա�(.hx�}���[ �K mX����ȕ��Z.�*"�\^�5L5�p.'�-�̡%�����L�e�Lfj�w �����Ռ >/Filter/FlateDecode/ID[ ]/Info 532 0 R/Lengt
Retrotope - Founded in 2006, Retrotope is creating a new... Facebook Log In Retrotope's Post Retrotope October 8, 2020 · Shared with Public Founded in 2006, Retrotope is creating a new category of drugs composed of proprietary compounds that treat degenerative diseases and cell death, thereby improving life as we age. We thrive in a challenging but collegiate, collaborative atmosphere where we can celebrate success while enjoying working as a team of 30-50 top professionals and discovering new inroads to improve human health. As an employee of Retrotope, you will be responsible for leadin
10-K 1 reta-10k_20171231.htm 10-K 2017 reta-10k_20171231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                     … 12 months (or for such shorter period that the Registrant was required to submit and post such files).    YES  ☒     NO   ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by r … rom our development program, will be sufficient to form the basis of a New Drug Application (NDA) submission to the FDA seeking approval of bardoxolone methyl for the treatment of CKD caused by Alport syndrome. We are developing omaveloxolone for the treatment of patients with FA, an inherited, debilitating, and degenerative neuromuscular disorder, caused by mutations in the gene for frataxin, a mitochondrial protein. Patients with FA are typically dependent on whe … broad applicability.  Once we have selected a class of small molecules, we apply their biological properties to clinical settings with unmet needs, and we triage opportunities based on development timeline and cost, regulatory pathway, and commercial opportunity.  After identifying suitable molecules for clinical development, we mitigate development risk by maintaining a diversified and broad clinical pipeline, rapidly analyzing data to determine the potential of ea … ; • The submission to the FDA of an investigational new drug (IND) application for human clinical testing, which must become effective before any human clinical trial commences; • Approval by an independent institutional review board (IRB), or ethics committee representing each clinical site before each clinical trial ma
Retrotope - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Cor … tia and other neurodegenerative disorders $215M AbbVie , The Dementia Discovery Fund & 20 others 65/100 75th Retrotope 2006 , Los Altos ( United States ) , Acquired Developer of therapeutics to treat neurodegenerative and ophthalmological diseases $69.6M Foundation Capital , Global Source Ventures ... & 12 others 53/100 Get insights and benchmarks for competitors of 2M+ companies! Sign up today! Looking for more details on Retrotope 's competitors? Click here to
RT001 / BioJiva RT001 / BioJiva - LARVOL DELTA Home Next Prev 1 to 25 Of 35 Go to page 1 2 December 04, 2022 Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia. (PubMed, J Neurol) - "The results of this study provide no evidence for a significant benefit of RT001 at the dosages tested in this Friedreich ataxia patient population." Journal • Ataxia • CNS Disorders • Friedreich ataxia • Movement Disorders Print Email More sharing Reddit StumbleUpon Delicious September 15, 2022 BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patient … ministration (FDA) related to its recently filed Investigational New Drug (IND) application for the use of RT001 in the treatment of PSP....Retrotope filed this IND for a PSP Phase 2/3 trial after 3 patients treated by physicians collaborating with Retrotope in PSP Expanded Access protocols showed encouraging results after more than a year on drug." FDA event • IND • New P2/3 trial • CNS Disorders • Progressive Supranuclear Palsy Print Email More sharing Reddit StumbleUpon De
Acknowledgments - Biosocial Surveys - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. more... An official website of the United States government Here's how you know The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard
Retrotope, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 31 May 2026 Retrotope, Inc. Subsidiary Company | 2006 | California, United States | 10-50 | www.retrotope.com Subsidiary Company | 2006 | California, United States | 10-50 | www.retrotope.com Last update 31 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Congenital Disorders Other Diseases Small molecule drug Chemical drugs Disease domain score A glimpse into t … trials for Friedreich's ataxia. In February 2025, the FDA accepted its New Drug Application (NDA) for the treatment of both pediatric and adult patients with Friedreich's ataxia, awarding it Priority Review with a PDUFA target action date of August 19, 2025. RT001, developed by Retrotope, is a deuterated ethyl linoleate that inhibits lipid peroxidation, aiming to mitigate cellular damage and improve mitochondrial function. It received Fast Track status from the FDA in Februar … ed frataxin protein expression. In February 2025, the FDA accepted the New Drug Application (NDA) for vatiquinone, intended for the treatment of both children and adults with Friedreich's ataxia. The application has been granted Priority Review. In January 2025, Solid Biosciences Inc. announced that the FDA has granted Fast Track designation to SGT-212, its AAV-based gene therapy candidate for treating Friedreich's ataxia. Friedreich's Ataxia Overview Friedreich's ataxia is a … ject to regulatory review and clearance.According to the agreement, Amylyx will grant exclusive rights to Neopharm for commercializing the therapy in the covered territory. In January 2023, uniQure N.V. and Apic Bio announced that they have entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), a rare, genetic form of ALS. Under the agreement, uniQure acquires global rights for the development and comm … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Instagram Instagram Log In Sign Up Close Never miss a post from curefa_org Sign up for Instagram to stay in the loop. Sign up Log in curefa_org • Follow More options curefa_org 321w 🔬 FARA’s Director of Patient Engagement, Susan Walther, recently conducted a Q&A with Retrotope’s Vice President of Medical Affairs, Dr. Mark Midei. They discuss the study drug 💊 and the effects of COVID-19 on the clinical trial. Click the link in the bio to watch the interview 👆. #CureFA . . . . . . . . . . #friedreichsataxia #raredisease #rarediseaseawareness #rarediseases #clinic #clinicalresearch #clinic
REATA PHARMACEUTICALS INC (Form: 10-K, Received: 02/19/2020 16:07:15) false 2019 FY 0001358762 --12-31 Yes Yes No Yes Large Accelerated Filer P6M true true true 2013 2014 2015 2009 2011 2012 2013 2014 2015 0.0135 0.0267 P3M 0.0267 0.0135 P6Y2M23D P6Y4M6D P6Y4M13D 0001358762 2019-01-01 2019-12-31 xbrli:shares 0001358762 us-gaap:CommonClassAMember 2020-02-13 0001358762 us-gaap:CommonClassBMember 2020-02-13 iso4217:USD 0001358762 2019-06-30 0001358762 2019-12-31 0001358762 2018-12-31 0001358762 us-gaap:CommonClassAMember 2019-12-31 0001358762 us-gaap:CommonClassAMember 2018-12-31 0001358762 us-ga … 12 months (or for such shorter period that the Registrant was required to submit such files).    YES  ☒     NO   ☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of “large accelerated filer”, “accelerated filer”, “smaller r … mine that additional trials or data are necessary in order to accept a new drug application for review and/or approval;   • our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;   • our plans to research, develop, and commercialize our product candidates;   • the commercialization of our product candidates, if approved;  … s Act ALS   Amyotrophic lateral sclerosis ANDA   Abbreviated new drug application ARB   Angiotensin receptor blockers ASC   Accounting Standards Codification ASU   Accounting Standards Update ATP   Adenosine triphosphate Bardoxolone   Bardoxolone methyl Bayer   Bayer AG CGMP   Current good manufacturing practice CKD   Chronic kidney disease CMO   Contract manufacturing organization CMS   Center for Medicare and Medic … Tax credits CRO   Contract research organization CTA   clinical trial application CTD-PAH   Pulmonary arterial hypertension associated with connective tissue disease Dartmouth   The Trustees of Dartmouth College DOJ   United States Department of Justice DSCSA   Drug Supply Chain Security Act DSMB   Data safety m
%PDF-1.7 %���� 1 0 obj >/Metadata 1008 0 R/ViewerPreferences 1009 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 11 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�� �r�6��3� �����@���s=j�9h�c� ��A���H�b�x� ��'�Oߺٲ ��b�x����X��dTՓ�4����u�hv�I'Ҏ�,��w�W���D"� ������� ��C${����������H��] �XF+T�6B���s ���^�Y�(�ƴA � \t��hE�sD��NIL�ĺ���g? ĎT7 ͥ��2zs Jz ����8 T)b0�>��]ݘ� ��ۖ" �4A��� *)�! !��9��t���gQ�$!�㑗�� ��S�i��z�d�5("��:�!�d � �z��� iq�Ĭ�E�u�D�%H� Qx
Pipeline About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Pipeline Pipeline Compound Indication Discovery/Preclinical Phase I Phase II Phase III RT001 Stabilized Linoleic … rd the clinic for the treatment of dry AMD with an investigation new drug (IND) application expected to be filed by the end of 2021. Clinical Programs : INAD – Infantile neuroaxonal dystrophy FA – Friedreich’s Ataxia ALS – Amyotrophic lateral sclerosis PSP – Progressive supranuclear palsy Prec linical Programs : AMD – Age-related macular degeneration Future target indications HD – Huntington’s disease SCA – Spinocerebellar ataxia MSA
Retrotope Reports Data from Phase 2/3 Clinical Trial of --> Accessibility: Skip TopNav Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD) October 06, 2021 07:00 ET | Source: Retrotope Retrotope Treatment with RT001 Results in Statistically Significant Improvements in Overall Survival and Progression Free Survival for INAD Patients as Compared to Control Benefits Supported by Totality of Evidence Across Modified Ashworth Spasticity Scale and Other Efficacy Measurements with RT001 Treat … can offer therapeutic benefit to patients battling INAD.” Retrotope intends to submit a pre-New Drug Application (NDA) meeting request with the FDA to discuss these study results and a path for submitting a regulatory approval application for RT001 in this ultra-rare, fatal disease. FDA has previously awarded Retrotope rare pediatric disease designation for RT001 in the treatment of INAD. “We are very pleased by these top-line results and excited to meet with the FDA to disc
%PDF-1.6 %���� 461 0 obj > endobj 486 0 obj >/Filter/FlateDecode/ID[ ]/Index[461 36]/Info 460 0 R/Length 111/Prev 1676653/Root 462 0 R/Size 497/Type/XRef/W[1 2 1]>>stream h�bbd``b`� �@��H0O, n>��� �� ��y�8"�@�=�$��o�Q@�:H�=�r@���}b� � L��1 ��!�3Z�0`�W endstream endobj startxref 0 %%EOF 496 0 obj >stream h�b```�6�T!b`��0p�(8X231 84�Lh`Lm�a:U$��0����Qׂ]d���� �Y (�ׄ�3���a��*����Q ���Be����� endstream endobj 462 0 obj >>> endobj 463 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageC]/Properties >>>/XObject >>>/Rotate 0/TrimBox[0.0 0.0 612.0 792.0]/ … ��5k��yݭ���ǯg��^y�kEk�����l�D_p߶������7Dm����o꿻1m��l�{��Mś� n�L�l� >stream application/pdf foxlogo_152 Adobe Illustrator CS3 2009-05-13T11:49:35-04:00 2010-06-01T14:27:16-04:00 2010-06-01T14:27:16-04:00 256 44 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fH … � ���#m=2ѹ'Å�o>�x�y��l߬e�S�UZ������~�O����1 endstream endobj 7 0 obj >stream application/pdf foxlogo_152 Adobe Illustrator CS3 2009-05-13T11:49:35-04:00 2010-06-01T14:27:16-04:00 2010-06-01T14:27:16-04:00 256 44 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fH … r �`bc����0S� &����c ]��:R���ãppp�#��U endstream endobj 28 0 obj >stream application/pdf fox_ar_tru8-f Adobe Illustrator CS3 2009-04-29T14:39:28-04:00 2010-05-27T15:03:30-04:00 2010-05-27T15:03:30-04:00 256 112 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx … H�����a��}' �:�fm���X��WʗX���) ��IS~}�#���( endstream endobj 39 0 obj >stream application/pdf fox_ar_tru8-f Adobe Illustrator CS3 2009-04-29T14:39:28-04:00 2010-05-27T15:03:30-04:00 2010-05-27T15:03:30-04:00 256 112 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQE
Company Overview About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home About Company Overview Company Overview Retrotope is a clinical-stage biopharmaceutical company focused o
FARA - Retrotope Granted Rare Pediatric Disease... Facebook Log In FARA's Post FARA February 25, 2021 · Shared with Public Retrotope Granted Rare Pediatric Disease Designation and Fast Track Designation from FDA for Lead Development Candidate, RT001, in FA. Click here to read the full press release: http://bit.ly/37LOToi FARA CEO Jen Farmer said, “These designations awarded to Retrotope are aligned with the high unmet need and call for urgency in the FA community. FA most commonly has onset of symptoms during childhood, ages 10-15 years, with significant progression and functional loss ta
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
About About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home About About Retrotope is developing a new class of drugs designed to combat the disease and cellular degeneration th
News - Global Source Ventures Skip to content Toggle navigation Global Source Ventures Home Portfolio About News Contact News Previous 1 2 3 4 … 8 Next October 19, 2021 Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit Read More October 13, 2021 Immusoft And Takeda Collaborate To Discover And Develop Cell Therapies For Rare Neurometabolic Disorders Read More October 6, 2021 Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural
Home Retrotope Inc. (650) 437-0700 - Reinforcing the molecules of life to combat degenerative diseases About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Reinforcing the Molecule
Get the job you really want - Zippia Verifying you are human. This may take a few seconds. (Loading widget...)
SSG Advises Retrotope in Sale of Assets to RTMFP Enterprises - ABF Journal Secured Research | Equipment Finance Originator | Monitor | Monitor Suite | Converge | STRIPES Leadership No Result View All Result Forward for Specialty Finance SUBSCRIBE Lender & Services Directory News People Economy All News Deals Magazine Magazine Issues Nominations Features Recruiting Events Advertise Contact Us News People Economy All News Deals Magazine Magazine Issues Nominations Features Recruiting Events Advertise Contact Us No Result View All Result No Result View All Result Home Deal Announcements SSG A
Press releases About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Press releases Press releases 2019 – Present 2016 - 2018 2013 - 2015 --> October 19, 2021 Positive Results … ministration (FDA) related to its recently filed Investigational New Drug (IND) application for the use of RT001 in the treatment of PSP. In addition, the FDA provided useful guidance and suggestions for detailed design elements of the trial. Read more April 16, 2020 Retrotope Initiates Project to Test RT001 in an Animal Model of Lung Damage to protect against COVID-19 impact Retrotope announced today that it has initiated experiments to determine if RT001, a drug that is abl
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts About Company Overview Management Team Board of Directors Science Advisors Neurology Advisors Ophthalmology Advisors Contacts Science Publications Collaborators Pipeline Infantile Neuroaxonal Dystrophy (INAD) Friedreich’s Ataxia (FA) Amyotrophic Lateral Sclerosis (ALS) Progressive Supranuclear Palsy (PSP) Dry AMD Future Targets Patient Resources Expanded Access Policy Clinical Trials Additional Resources News & Events Press Releases News Events Videos Careers --> Home Pres … ration (AMD) – Retrotope expects to file an Investigational New Drug (IND) application for RT011 in mid-2021 and initiate first-in-human clinical studies in dry AMD soon thereafter. Unlike most other dry AMD treatments in development, RT011 is an oral drug, offering key administration advantages. Promising preclinical results have suggested the ability of RT011 to protect retinal cells and preserve photoreceptors in various AMD-related animal models
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
RT001 - Friedreich's Ataxia Research Alliance Skip to main content Accessibility Search Understanding FA What is Friedreich’s ataxia? Signs and Symptoms Journey to an FA Diagnosis Genetics of FA Treating and Managing FA Newly Diagnosed What You Need to Know Connect with Others in the Community Managing FA Clinical Management Guidelines Assembling a Care Team Treatment for FA Approved Treatments For Healthcare Professionals Terms to Know (Glossary) Research Grant Program Grant Application Process Grant Types FARA Funded Grants Grant Priorities Opportunities for Young Investigators Research … to Retrotope Link to previous studies Inactive: Discovery 2012: FARA awarded a grant for testing Retrotope compounds in established cell models. Results of this work have been published and can be accessed in the Related Publications section below. Inactive: Regulatory October 2012: Retrotope had an introductory (pre-IND) meeting with the FDA. At that meeting, the FDA provided clear information and guidance on the requirements for Retrotope’s Investigational New Drug ( … idance on the requirements for Retrotope’s Investigational New Drug (IND) Application for a Phase Ib trial of Retrotope’s drug for FA. 2013: FARA awarded a grant to Retrotope to assist with the manufacturing of drug product and toxicology studies required for the IND filing. 2015: Retrotope filed their IND with FDA and announced enrollment of a Phase Ib/IIa study of RT001. June 2016 : Retrotope announced that FDA granted Orphan Drug Designation for RT001 in FA. In … , disease state, and exploratory endpoints in patients with FA. FARA provided a grant to Retrotope to support participant travel for the study. September 2016: Retrotope, along with Dr. Theresa Zesiewicz, study Principal Investigator, presented results at the annual USF symposium of the trial of RT001. The trial met all of its primary safety, tolerability and pharmacodynamics (PK) goals. While biological activity was not a primary goal of the study, a number of clinically imp … ; Press FARA Store Policies Terms and Conditions Informed Stay Informed Captcha Submit If you are human, leave this field blank. Follow us © 2026 . Friedreich's Ataxia Research Alliance. Accessibility Sitemap Cookie Preferences Site by Rouge
Biopharma Company Retrotope Files for Bankruptcy in Delaware Skip to content Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world For Customers Bloomberg Anywhere Remote Login Software Updates Manage Products and Account Information Support Ame … , Inc. All Rights Reserved Sign Up For Newsletters View Bloomberg Law's YouTube Submit A News Tip About Us Contact Us pro.bloomberglaw.com Do Not Sell Or Share My Personal Information 24/7 BLAW® HELP DESK 888.560.2529 [email protected] Terms of Service • Privacy Policy Copyright • Accessibility © 2026 Bloomberg Industry Group, Inc. All Rights Reserved © 2026 Bloomberg Industry Group, Inc. All Rights Reserved
FARA - 🔬 Retrotope provided an informational patient... Facebook Log In FARA's Post FARA October 23, 2019 · Shared with Public Retrotope provided an informational patient webinar on October 21, 2019. This webinar covered the results of the initial clinical trial of RT001 and the plans for an upcoming follow-up clinical trial – RT001-006. RT001 is an oral drug that “fortifies” mitochondrial membranes to minimize oxidative damage and to protect cellular function and energy production. A recording of the webinar can be viewed here bit.ly/2MDwtvF . #CureFA All reactions: 32 1 comment 2 share
Longevity Conferences | Dr. Mikhail S. Shchepinov, CSO at Retrotope, Inc
Mikhail Shchepinov, PhD | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Research Strategy Key Research Initiatives Parkinson’s Biomarkers Prizes Understanding Parkinson's Under … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways … Retrotope, Inc., and is Principal Investigator on this Retrotope Rapid Response Award. Born in Moscow, USSR, Dr. Shchepinov received his MS in chemistry and biotechnology from the Mendeleev Institute of Chemical Technology, Moscow, and a PhD in bioorganic chemistry from the Institute of Bioorganic Chemistry, Moscow, in 1994. He completed postdoctoral research in the Department of Biochemistry, University of Oxford, UK, from 1995‰ÛÒ2000, focusing on the areas of DNA chip techn